Chargement en cours...
Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors
INTRODUCTION: Hyperkalemia (potassium >5.0 mEq/L) affects heart failure patients with renal disease regardless of the use of renin–angiotensin–aldosterone system inhibitors (RAASi). The open-label TOURMALINE study showed that patiromer, a sodium-free, nonabsorbed potassium binder, lowers serum po...
Enregistré dans:
| Publié dans: | J Cardiovasc Pharmacol Ther |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6193203/ https://ncbi.nlm.nih.gov/pubmed/30103622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1074248418788334 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|